



Clinical trial results:

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Summary

EudraCT number	2018-001028-21
Trial protocol	NO ES
Global end of trial date	22 July 2022

Results information

Result version number	v2 (current)
This version publication date	24 September 2023
First version publication date	03 August 2023
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	D6070C00005
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03611556
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	MedImmune, LLC
Sponsor organisation address	One MedImmune Way, Gaithersburg, Maryland, United States, 20878
Public contact	Global Clinical Lead, AstraZeneca Clinical study Information Center, +1 8772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca Clinical study Information Center, +1 8772409479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 November 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 July 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of the study are: 1. To assess the safety and tolerability of oleclumab (Ole) plus durvalumab (Durva) in combination with chemotherapy administered in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) in dose escalation phase (Part 1). 2. To evaluate the preliminary antitumor activity of ole with or without durva in combination with gemcitabine (Gem) and nab-paclitaxel (nab-pacli) compared to gem and nab-pacli administered in participants with first-line metastatic PDAC in dose expansion phase (Part 2). 3. To evaluate the preliminary antitumor activity of ole with or without durva in combination with modified regimen of leucovorin (folinic acid), 5-fluorouracil, and oxaliplatin (mFOLFOX) compared to mFOLFOX administered in participants with second-line (2L) metastatic PDAC in dose expansion phase (Part 2).

Protection of trial subjects:

The conduct of this clinical study met all local and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization guideline: Good Clinical Practice, and applicable regulatory requirements. Participants signed an informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 June 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 21
Country: Number of subjects enrolled	Norway: 4
Country: Number of subjects enrolled	Spain: 24
Country: Number of subjects enrolled	United States: 146
Worldwide total number of subjects	195
EEA total number of subjects	28

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	102
From 65 to 84 years	92
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 29 sites in 4 countries (Australia, Norway, Spain, and the United States of America).

Pre-assignment

Screening details:

A total of 25 participants were treated in dose escalation part of this study. A total of 188 participants were randomized in dose expansion part of this study of which 170 participants were treated (18 participants were randomized but not treated). Results are presented for 195 treated participants only.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli

Arm description:

Participants with first-line (1L) metastatic disease received intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) until disease progression (PD), intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	MEDI4736
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of durvalumab 1500 mg Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of gemcitabine 1000 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of nab-paclitaxel 125 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-paccli
------------------	---

Arm description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of nab-paclitaxel 125 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of gemcitabine 1000 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	MEDI4736
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of durvalumab 1500 mg Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
------------------	--

Arm description:

Participants with 2L metastatic disease received IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX

(oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; fluorouracil [5-FU] 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	mFOLFOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of mFOLFOX (oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; 5-fluorouracil [5-FU] 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	MEDI4736
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of durvalumab 1500 mg Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
------------------	--

Arm description:

Participants with 2L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; 5-FU 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	mFOLFOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of mFOLFOX (oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; 5-FU 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and

15 and then repeated on a Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	MEDI4736
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of durvalumab 1500 mg Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-expansion, Gem + nab-pacli
------------------	---------------------------------

Arm description:

Participants with 1L metastatic disease received IV infusions of chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of nab-paclitaxel 125 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of gemcitabine 1000 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
------------------	---

Arm description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of nab-paclitaxel 125 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of gemcitabine 1000 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm title	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-paclitaxel
------------------	--

Arm description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Arm type	Experimental
Investigational medicinal product name	Oleclumab
Investigational medicinal product code	
Other name	MEDI9447
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of nab-paclitaxel 125 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of gemcitabine 1000 mg/m² on Days 1, 8, and 15 and then repeated on Q4W schedule until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	MEDI4736
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion of durvalumab 1500 mg Q4W until PD, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Number of subjects in period 1	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacl	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacl	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
Started	7	7	3
Completed	0	0	0
Not completed	7	7	3
Adverse event, serious fatal	1	-	-
Death due to disease progression	6	7	3
Death due to toxicity related to study drug	-	-	-
Consent withdrawn by subject	-	-	-
Death, reason unspecified	-	-	-
Sponsor decision	-	-	-
Reasons	-	-	-

Number of subjects in period 1	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Started	8	62	38
Completed	0	0	0
Not completed	8	62	38
Adverse event, serious fatal	-	3	1
Death due to disease progression	8	42	31
Death due to toxicity related to study drug	-	-	-
Consent withdrawn by subject	-	4	2
Death, reason unspecified	-	2	-
Sponsor decision	-	9	4
Reasons	-	2	-

Number of subjects in period 1	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl
Started	70
Completed	0
Not completed	70
Adverse event, serious fatal	3
Death due to disease progression	49
Death due to toxicity related to study drug	1
Consent withdrawn by subject	4
Death, reason unspecified	-
Sponsor decision	12
Reasons	1

Baseline characteristics

Reporting groups

Reporting group title	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli
-----------------------	--

Reporting group description:

Participants with first-line (1L) metastatic disease received intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli
-----------------------	--

Reporting group description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
-----------------------	--

Reporting group description:

Participants with 2L metastatic disease received IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; fluorouracil [5-FU] 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
-----------------------	--

Reporting group description:

Participants with 2L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m² IV; folinic acid 400 mg/m² IV; 5-FU 400 mg/m² IV bolus followed by 2400 mg/m² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-expansion, Gem + nab-pacli
-----------------------	---------------------------------

Reporting group description:

Participants with 1L metastatic disease received IV infusions of chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
-----------------------	---

Reporting group description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group title	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli
-----------------------	---

Reporting group description:

Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Reporting group values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
Number of subjects	7	7	3

Age categorical Units: Participants			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	4	1
From 65-84 years	5	3	2
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	66.7	59.6	67.0
standard deviation	± 12.8	± 11.4	± 14.9
Sex: Female, Male Units: Participants			
Female	3	4	1
Male	4	3	2
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	1	0
White	6	5	3
More than one race	0	1	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	7	7	3
Unknown or Not Reported	0	0	0

Reporting group values	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Number of subjects	8	62	38
Age categorical Units: Participants			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	29	23
From 65-84 years	5	32	15
85 years and over	0	1	0

Age Continuous Units: Years arithmetic mean standard deviation	64.8 ± 4.8	65.6 ± 8.0	62.5 ± 11.1
Sex: Female, Male Units: Participants			
Female	4	26	17
Male	4	36	21
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	5	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	2	3	2
White	6	54	33
More than one race	0	0	1
Unknown or Not Reported	0	0	1
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	0	1
Not Hispanic or Latino	7	61	37
Unknown or Not Reported	0	1	0

Reporting group values	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	Total	
Number of subjects	70	195	
Age categorical Units: Participants			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	40	102	
From 65-84 years	30	92	
85 years and over	0	1	
Age Continuous Units: Years arithmetic mean standard deviation	62.9 ± 8.3	-	
Sex: Female, Male Units: Participants			
Female	34	89	
Male	36	106	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	1	
Asian	1	7	

Native Hawaiian or Other Pacific Islander	0	1	
Black or African American	2	10	
White	64	171	
More than one race	0	2	
Unknown or Not Reported	2	3	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	3	
Not Hispanic or Latino	69	191	
Unknown or Not Reported	0	1	

End points

End points reporting groups

Reporting group title	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli
Reporting group description: Participants with first-line (1L) metastatic disease received intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli
Reporting group description: Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
Reporting group description: Participants with 2L metastatic disease received IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m ² IV; folinic acid 400 mg/m ² IV; fluorouracil [5-FU] 400 mg/m ² IV bolus followed by 2400 mg/m ² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Reporting group description: Participants with 2L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m ² IV; folinic acid 400 mg/m ² IV; 5-FU 400 mg/m ² IV bolus followed by 2400 mg/m ² continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-expansion, Gem + nab-pacli
Reporting group description: Participants with 1L metastatic disease received IV infusions of chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
Reporting group description: Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Reporting group title	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli
Reporting group description: Participants with 1L metastatic disease received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	
Subject analysis set title	Gem + nab-pacli: CD73 level = High
Subject analysis set type	Sub-group analysis
Subject analysis set description: In dose-expansion phase, participants with 1L metastatic disease and high CD73 levels received IV infusions of chemotherapy of gemcitabine 1000 mg/m ² and nab-paclitaxel 125 mg/m ² , both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.	

Subject analysis set title	Ole 3000 mg + Gem + nab-pacli: CD73 level = High
Subject analysis set type	Sub-group analysis

Subject analysis set description:

In dose-expansion phase, participants with 1L metastatic disease and high CD73 levels received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Subject analysis set title	Ole 3000 mg + Durva + Gem + nab-pacli: CD73 level = High
Subject analysis set type	Sub-group analysis

Subject analysis set description:

In dose-expansion phase, participants with 1L metastatic disease and high CD73 levels received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Subject analysis set title	Gem + nab-pacli: CD73 level = Low
Subject analysis set type	Sub-group analysis

Subject analysis set description:

In dose-expansion phase, participants with 1L metastatic disease and low CD73 levels received IV infusions of chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Subject analysis set title	Ole 3000 mg + Gem + nab-pacli: CD73 level = Low
Subject analysis set type	Sub-group analysis

Subject analysis set description:

In dose-expansion phase, participants with 1L metastatic disease and low CD73 levels received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Subject analysis set title	Ole 3000 mg + Durva + Gem + nab-pacli: CD73 level = Low
Subject analysis set type	Sub-group analysis

Subject analysis set description:

In dose-expansion phase, participants with 1L metastatic disease and low CD73 levels received IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m², both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion was met.

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase

End point title	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase ^{[1][2]}
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 65.7 weeks (maximum observed duration)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Participants				
Any TEAEs	7	7	3	8
Any TSEAEs	4	6	0	4

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase

End point title	Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase ^[3] ^[4]
-----------------	--

End point description:

DLT: Any study drug related Grade (G)3/higher toxicity including: any G4 immune-mediated AEs, \geq G3 colitis/pneumonitis(PN)/interstitial lung disease (ILD), \geq G3 nausea/vomiting/diarrhea that did not resolve to G2/less in 3 days of maximal supportive care (MSC), G2 PN/ILD that did not resolve in 7 days of starting MSC, G4 anemia, G3 anemia with clinical sequelae/ >2 units of red blood cells transfusion, G4 thrombocytopenia(TP)/neutropenia ≥ 7 days, G3/4 TP with \geq G3 hemorrhage, G4 febrile neutropenia(FN), G3 FN ≥ 5 days with MSC, isolated G3; liver transaminase elevation(LTE)/total bilirubin(TBL) that did not downgrade to G1/less in 14 days of onset, isolated G4 LTE/TBL, AST/ALT $>3 \times$ upper limit normal (ULN) and concurrent TBL $>2 \times$ ULN, any other toxicity judged by Dose Escalation Committee. The DLT-evaluable population included all participants who received planned doses of study drugs in dose-escalation phase and completed safety follow-up/experienced any DLT during DLT-

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to 28 days after the first dose of study drugs

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	6	3	8
Units: Participants	0	0	0	1

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase

End point title	Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase ^{[5][6]}
-----------------	---

End point description:

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 65.7 weeks (maximum observed duration)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Participants				
Pyrexia	3	3	0	1
Dyspnoea	1	0	0	0
Dyspnoea exertional	0	1	0	0
Hypotension	2	1	0	1
Temperature intolerance	0	0	1	0
Hypertension	0	0	0	1

Statistical analyses

Primary: Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase

End point title	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase ^[7] ^[8]
-----------------	--

End point description:

Number of participants with abnormal ECG parameters reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 65.7 weeks (maximum observed duration)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Participants				
Atrial fibrillation	0	1	0	0
Tachycardia	0	1	0	0
Atrioventricular block	0	0	0	1

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase

End point title	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase ^[9] ^[10]
-----------------	---

End point description:

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 65.7 weeks (maximum observed duration)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Participants				
Anaemia	3	3	1	0
Neutropenia	2	2	2	1
Thrombocytopenia	2	2	2	1
Hypothyroidism	0	1	0	1
Alanine aminotransferase increased	3	4	0	2
Aspartate aminotransferase increased	3	3	0	3
Blood alkaline phosphatase increased	2	1	0	1
Blood bilirubin increased	1	0	0	1
Blood creatinine increased	0	3	0	0
Blood glucose decreased	1	0	0	0
International normalised ratio increased	1	0	0	0
Lymphocyte count decreased	0	1	0	2
Neutrophil count decreased	0	2	1	3
Platelet count decreased	1	3	1	2
White blood cell count decreased	0	2	0	2
Hypoalbuminaemia	0	2	0	1
Hypocalcaemia	0	1	0	1
Hypokalaemia	0	3	0	2
Hypomagnesaemia	1	2	0	1
Hyponatraemia	0	2	0	2
Hypophosphataemia	0	1	0	0
Proteinuria	1	0	0	0
Hyperthyroidism	0	0	0	1
Amylase increased	0	0	1	1
Gamma-glutamyltransferase increased	0	0	0	1
Lipase increased	0	0	0	1

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in Dose Expansion Phase

End point title	Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in Dose Expansion Phase ^[11]
-----------------	---

End point description:

The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (LN) (target [TLN] and non-target [NTLN]) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. The intent-to treat (ITT) population included all participants who were randomized and received any study drugs and were analyzed according to randomized treatment assignment.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Percentage of Participants				
number (confidence interval 95%)	29.0 (18.2 to 41.9)	21.1 (9.6 to 37.3)	32.9 (22.1 to 45.1)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1 (a)
Comparison groups	Dose-expansion, Gem + nab-pacl v Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3614 ^[12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Rate difference
Point estimate	-8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.6
upper limit	12.1

Notes:

[12] - Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by CD73 level.

Statistical analysis title	Statistical Analysis 2 (a)
Comparison groups	Dose-expansion, Gem + nab-pacl v Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl

Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6503 ^[13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Rate difference
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.2
upper limit	20.7

Notes:

[13] - Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by CD73 level.

Statistical analysis title	Statistical Analysis 2 (b)
Comparison groups	Dose-expansion, Gem + nab-paclitaxel v Dose-expansion, Ole 3000 mg + Durva + Gem + nab-paclitaxel
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6503 ^[14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Rate difference
Point estimate	3.8
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-7.4
upper limit	15

Notes:

[14] - Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by CD73 level.

Statistical analysis title	Statistical Analysis 1 (b)
Comparison groups	Dose-expansion, Gem + nab-paclitaxel v Dose-expansion, Ole 3000 mg + Gem + nab-paclitaxel
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3614 ^[15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Rate difference
Point estimate	-8
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-20.9
upper limit	5.2

Notes:

[15] - Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by CD73 level.

Secondary: Number of Participants With TEAEs and TESAEs in Dose Expansion Phase

End point title	Number of Participants With TEAEs and TESAEs in Dose Expansion Phase ^[16]
-----------------	--

End point description:

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 172.1 weeks (maximum observed duration)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants				
Any TEAEs	62	37	70	
Any TESAEs	34	24	37	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase

End point title	Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase ^[17]
-----------------	--

End point description:

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 172.1 weeks (maximum observed duration)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants				
Hypothermia	0	0	1	
Pyrexia	15	12	21	
Dyspnoea	7	6	8	
Dyspnoea exertional	1	1	2	
Hypertension	2	3	11	
Hypotension	3	4	4	
Orthostatic hypotension	1	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase

End point title	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase ^[18]
-----------------	---

End point description:

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 172.1 weeks (maximum observed duration)

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants				
Anaemia	17	14	28	
Febrile neutropenia	0	1	3	

Leukocytosis	1	0	1	
Leukopenia	1	2	3	
Lymphopenia	2	0	2	
Neutropenia	22	15	16	
Thrombocytopenia	6	7	13	
Thrombocytosis	2	0	1	
Hyperthyroidism	0	0	3	
Hypothyroidism	0	0	7	
Hypertransaminaemia	0	1	0	
Alanine aminotransferase decreased	1	0	0	
Alanine aminotransferase increased	8	9	16	
Amylase increased	1	0	1	
Aspartate aminotransferase increased	11	8	15	
Blood albumin decreased	1	0	0	
Blood alkaline phosphatase increased	3	2	8	
Blood bilirubin increased	3	3	2	
Blood creatinine increased	2	0	8	
Blood glucose increased	0	2	0	
Blood lactate dehydrogenase increased	1	0	3	
Blood magnesium decreased	0	1	0	
Blood oestrogen decreased	0	1	0	
Gamma-glutamyltransferase increased	6	1	8	
Haemoglobin decreased	0	0	1	
International normalised ratio increased	0	0	1	
Lipase increased	0	1	2	
Liver function test increased	1	0	0	
Lymphocyte count decreased	4	2	6	
Neutrophil count	0	0	1	
Neutrophil count decreased	19	8	24	
Platelet count decreased	13	9	20	
Troponin I increased	1	0	0	
White blood cell count decreased	6	6	10	
White blood cell count increased	0	1	0	
Hyperglycaemia	4	2	6	
Hyperkalaemia	1	1	1	
Hypoalbuminaemia	3	2	6	
Hypocalcaemia	2	2	3	
Hypoglycaemia	0	0	2	
Hypokalaemia	4	2	8	
Hypomagnesaemia	4	3	6	
Hyponatraemia	8	0	3	
Hypophosphataemia	1	0	0	
Hypovolaemia	1	0	0	
Iron deficiency	0	0	1	
Type 2 diabetes mellitus	0	1	0	
Proteinuria	0	1	1	

Statistical analyses

Secondary: Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase

End point title	Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase ^[19]
-----------------	---

End point description:

Number of participants with abnormal ECG parameters reported as TEAEs are reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 172.1 weeks (maximum observed duration)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants				
Supraventricular tachycardia	0	1	0	
Tachycardia	2	3	3	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase

End point title	Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase ^[20]
-----------------	--

End point description:

DC: defined as confirmed CR, PR, or stable disease (SD) (maintained for ≥ 8 weeks). The CR is disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from first documentation date. The SD is neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), and no new lesions. The PD is at least 20% increase in SoD of TLs and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Percentage of Participants				
number (confidence interval 95%)	42.9 (9.9 to 81.6)	71.4 (29.0 to 96.3)	66.7 (9.4 to 99.2)	62.5 (24.5 to 91.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase

End point title	Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase ^[21]
-----------------	--

End point description:

The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received. The numbers of confidence interval (CI) '0 to 0' signified that there was zero responder in the specified cohort, so 95% CI could not be calculated.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: Percentage of Participants				
number (confidence interval 95%)	0 (0 to 0)	14.3 (0.4 to 57.9)	0 (0 to 0)	12.5 (0.3 to 52.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Overall Survival Events in Dose Expansion Phase

End point title	Number of Participants With Overall Survival Events in Dose Expansion Phase ^[22]
-----------------	---

End point description:

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants with event				
number (not applicable)	47	32	53	

Statistical analyses

Statistical analysis title	Statistical Analysis 2
----------------------------	------------------------

Statistical analysis description:

Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.

Comparison groups	Dose-expansion, Gem + nab-pacli v Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli
-------------------	---

Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.498
upper limit	1.131

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Dose-expansion, Gem + nab-paclitaxel v Dose-expansion, Ole 3000 mg + Gem + nab-paclitaxel
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.983

Secondary: Number of Participants With Progression-free Survival (PFS) Events According to RECIST v1.1 in Dose Expansion Phase

End point title	Number of Participants With Progression-free Survival (PFS) Events According to RECIST v1.1 in Dose Expansion Phase ^[23]
End point description:	
<p>The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. PD: at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment.</p>	
End point type	Secondary
End point timeframe:	
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)	

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end

point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Participants with event				
number (not applicable)	43	32	51	

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Dose-expansion, Gem + nab-pacl v Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.719
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.468
upper limit	1.105

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Dose-expansion, Gem + nab-pacl v Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.726
upper limit	1.837

Secondary: Overall Survival in Dose Expansion Phase

End point title	Overall Survival in Dose Expansion Phase ^[24]
-----------------	--

End point description:

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Months				
median (confidence interval 95%)	10.8 (8.2 to 13.2)	8.9 (6.9 to 11.5)	12.9 (10.1 to 15.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase

End point title	Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase ^[25]
-----------------	--

End point description:

Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Months				
median (confidence interval 95%)	6.7 (5.5 to 9.0)	5.6 (3.5 to 7.5)	7.5 (5.5 to 10.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase

End point title	Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase ^[26]
-----------------	---

End point description:

DoR: Time from first documentation of OR until first documentation of PD/death due to any cause, whichever occurred first. OR: Confirmed CR/PR based on RECIST v1.1. CR: Disappearance of all TLs and NTLs, any pathological TLN and NTLN must had reduction in short axis <10 mm and no new lesions. PR: At least 30% decrease in SoD of TLs and no new lesions. Confirmation of CR and PR is required by repeat, consecutive assessment no less than 4 weeks from first documentation date. PD: At least 20% increase in SoD of TLs and absolute increase of at least 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion/s. DoR is assessed using Kaplan-Meier method. ITT population included all participants who received any study drugs and analyzed according to randomized treatment assignment. DoR is assessed for only those participants who had OR. The arbitrary number 99.99 signified upper limit confidence interval (CI) could not be derived due to insufficient events being observed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18	8	23	
Units: Months				
median (confidence interval 95%)	7.2 (4.9 to	12.9 (2.2 to	9.5 (5.7 to	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase

End point title	Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase ^[27]
-----------------	---

End point description:

DC: defined as confirmed CR, PR, or stable disease (SD) (maintained for ≥ 8 weeks). The CR is disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from first documentation date. The SD is neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, and no new lesions. The PD is at least 20% increase in SoD of TLs and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported. The ITT population included all participants who were randomized and received any study drugs and analyzed according to randomized treatment assignment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	38	70	
Units: Percentage of Participants				
number (confidence interval 95%)	66.1 (53.0 to 77.7)	73.7 (56.9 to 86.6)	75.7 (64.0 to 85.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

End point title	Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
-----------------	--

End point description:

OR: Best overall response of confirmed CR/PR based on RECIST v1.1. CR: Disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must had reduction in short axis <10 mm, and no new lesions. PR: At least 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than weeks from first documentation date. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. CD73 low: No CD73 expression in tumor cells or <50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in ≥50% of tumor cells. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment. Here, "number of subjects analyzed" (N) signified those participants who had high or low levels of CD73.

End point type	Secondary
End point timeframe:	
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)	

End point values	Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High	Gem + nab-pacl: CD73 level = Low
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	46	27	51	16
Units: Percentage of Participants				
number (confidence interval 95%)	23.9 (12.6 to 38.8)	22.2 (8.6 to 42.3)	31.4 (19.1 to 45.9)	43.8 (19.8 to 70.1)

End point values	Ole 3000 mg + Gem + nab-pacl: CD73 level = Low	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	11	19		
Units: Percentage of Participants				
number (confidence interval 95%)	18.2 (2.3 to 51.8)	36.8 (16.3 to 61.6)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Gem + nab-pacl: CD73 level = High
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Rate difference
Point estimate	-1.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.2
upper limit	21.9

Statistical analysis title	Statistical Analysis 3
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Rate difference
Point estimate	-25.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.3
upper limit	13.9

Statistical analysis title	Statistical Analysis 4
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Rate difference
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39.1
upper limit	26.6

Statistical analysis title	Statistical Analysis 2
Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Rate difference
Point estimate	7.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.6
upper limit	27

Secondary: Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase

End point title	Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase
-----------------	--

End point description:

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in ≥50% of tumor cells. The number of participants with overall survival events (deaths) is reported. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment. Here, "number of subjects analyzed" (N) signified those participants who had high or low levels of CD73.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

End point values	Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High	Gem + nab-pacl: CD73 level = Low
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	46	27	51	16
Units: Participants with events				
number (not applicable)	37	22	39	10

End point values	Ole 3000 mg + Gem + nab-pacl: CD73 level = Low	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	11	19		
Units: Participants with events				
number (not applicable)	10	14		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Gem + nab-pacl: CD73 level = High
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.173
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.676
upper limit	1.985

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.472
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.638
upper limit	3.576

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.549

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.622
upper limit	3.917

Statistical analysis title	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.

Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.605
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.377
upper limit	0.968

Secondary: Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase

End point title	Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase
-----------------	---

End point description:

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in ≥50% of tumor cells. The ITT population included all participants who were randomized and received any amount of study drugs and were analyzed according to randomized treatment assignment. Here, "number of subjects analyzed" (N) signified those participants who had high or low levels of CD73.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

End point values	Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High	Gem + nab-pacl: CD73 level = Low
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	46	27	51	16
Units: Months				
median (confidence interval 95%)	9.9 (6.8 to 12.2)	7.9 (4.2 to 9.7)	12.1 (8.6 to 15.0)	22.2 (10.2 to 33.6)

End point values	Ole 3000 mg + Gem + nab-pacl: CD73 level = Low	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	11	19		
Units: Months				
median (confidence interval 95%)	16.0 (5.7 to 22.6)	16.1 (10.3 to 21.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

End point title	Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
End point description:	
<p>PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD: $\geq 20\%$ increase in SoD of TLs and an absolute increase of ≥ 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/$<50\%$ of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in $\geq 50\%$ of tumor cells. Number of participants with PFS events is reported. ITT population was analyzed for this endpoint. "Number of subjects analyzed" (N) signified those participants who had high/low levels of CD73.</p>	
End point type	Secondary
End point timeframe:	
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)	

End point values	Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High	Gem + nab-pacl: CD73 level = Low
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	46	27	51	16
Units: Participants with event				
number (not applicable)	35	23	39	8

End point values	Ole 3000 mg + Gem + nab-pacl: CD73 level = Low	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	11	19		
Units: Participants with event				
number (not applicable)	9	12		

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.598
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.366
upper limit	0.973

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = High v Ole 3000 mg + Gem + nab-pacl: CD73 level = High

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.004
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.584
upper limit	1.693

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.374
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	3.707

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.	
Comparison groups	Gem + nab-pacl: CD73 level = Low v Ole 3000 mg + Gem + nab-pacl: CD73 level = Low
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.933
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.716
upper limit	5.437

Secondary: Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab

End point title	Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab ^[28]
-----------------	--

End point description:

Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at ≥ 2 post-baseline assessments (with < 16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration. The ADA evaluable oleclumab population included all participants who received oleclumab, analyzed according to the treatment they actually received, and who had a non-missing baseline ADA result and at least one non-missing post-baseline ADA result.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	3	7
Units: Participants				
ADA positive at baseline	0	0	0	0
ADA positive post-baseline	1	0	0	1
Persistent Positive	1	0	0	1
Transient Positive	0	0	0	0
Treatment-boosted ADA	0	0	0	0

End point values	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	31	63		
Units: Participants				
ADA positive at baseline	0	0		
ADA positive post-baseline	1	0		
Persistent Positive	0	0		
Transient Positive	1	0		
Treatment-boosted ADA	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

End point title	Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
-----------------	---

End point description:

PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of subsequent anticancer treatment prior to progression. PD: $\geq 20\%$ increase in SoD of TLs and absolute increase of ≥ 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/ $<50\%$ of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in $\geq 50\%$ of tumor cells. ITT population was analyzed for this endpoint. "Number of subjects analyzed"(N) signified those participants who had high/low levels of CD73. Arbitrary number 99.99 signified upper limit CI could not be derived due to

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

End point values	Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Gem + nab-pacl: CD73 level = High	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = High	Gem + nab-pacl: CD73 level = Low
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	46	27	51	16
Units: Months				
median (confidence interval 95%)	5.6 (3.7 to 7.4)	5.2 (1.9 to 6.3)	5.5 (4.4 to 9.3)	10.5 (6.9 to 99.99)

End point values	Ole 3000 mg + Gem + nab-pacl: CD73 level = Low	Ole 3000 mg + Durva + Gem + nab-pacl: CD73 level = Low		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	11	19		
Units: Months				
median (confidence interval 95%)	7.6 (3.3 to 11.2)	10.9 (5.7 to 13.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Positive ADA to Durvalumab

End point title	Number of Participants With Positive ADA to Durvalumab ^[29]
End point description:	
<p>Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at ≥ 2 post-baseline assessments (with < 16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration. The ADA evaluable durvalumab population included all participants who received durvalumab, analyzed according to the treatment they actually received, and who had a non-missing baseline ADA result and at least one non-missing post-baseline ADA result.</p>	
End point type	Secondary
End point timeframe:	
Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)	
Notes:	
<p>[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.</p> <p>Justification: Only those baseline period arms for which analysis was planned were reported in the end point.</p>	

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	3	7
Units: Participants				
ADA positive at baseline	0	0	0	0
ADA positive post-baseline	1	0	0	2
Persistent Positive	1	0	0	2
Transient Positive	0	0	0	0
Treatment-boosted ADA	0	0	0	0

End point values	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: Participants				
ADA positive at baseline	2			
ADA positive post-baseline	0			
Persistent Positive	0			
Transient Positive	0			
Treatment-boosted ADA	0			

Statistical analyses

Secondary: Serum Concentrations of Oleclumab

End point title	Serum Concentrations of Oleclumab ^[30]
-----------------	---

End point description:

Serum concentrations of oleclumab are reported. Pharmacokinetic (PK) evaluable oleclumab population included all participants who received at least one dose of oleclumab and who had at least one reportable PK concentration. Here, n (number analyzed) denotes those participants who were analyzed for the specified time points. The arbitrary numbers 0.99999 and 99999 signified that the geometric mean and geometric CV% were not calculated at the time point. This was because, as per sponsor convention, three observations > Lower Limit of Quantification were required as a minimum for a plasma concentration to be summarised. Otherwise, the statistics were not calculated at the time point for the specified arm. The arbitrary numbers 999.99 and 9999.9 signified that the geometric mean and geometric CV% could not be calculated as no participant was analysed at that time point for the specified arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Ten minutes (mins) (\pm 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: $\mu\text{g/mL}$				
geometric mean (geometric coefficient of variation)				
C1D1 (EOI) (n=7,7,3,7,37,70)	297.6 (\pm 25.70)	710.2 (\pm 21.42)	412.7 (\pm 11.12)	734.6 (\pm 41.01)
C3D1 (pre-dose) (n=3,5,3,4,27,57)	128.6 (\pm 10.00)	211.5 (\pm 73.40)	134.3 (\pm 141.5)	368.9 (\pm 2.461)
C3D1 (EOI) (n=2,5,3,4,25,57)	0.99999 (\pm 99999)	870.3 (\pm 21.86)	571.1 (\pm 15.75)	1181 (\pm 24.97)
C5D1 (pre-dose) (n=1,3,0,4,20,45)	0.99999 (\pm 99999)	73.19 (\pm 130.2)	999.99 (\pm 9999.9)	235.7 (\pm 27.68)
C5D1 (EOI) (n=1,3,0,4,20,45)	0.99999 (\pm 99999)	948.3 (\pm 44.90)	999.99 (\pm 9999.9)	1057 (\pm 14.88)

End point values	Dose-expansion, Ole 3000 mg + Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	70		
Units: $\mu\text{g/mL}$				
geometric mean (geometric coefficient of variation)				

C1D1 (EOI) (n=7,7,3,7,37,70)	704.4 (± 30.28)	725.9 (± 34.69)		
C3D1 (pre-dose) (n=3,5,3,4,27,57)	164.8 (± 324.1)	226.8 (± 70.41)		
C3D1 (EOI) (n=2,5,3,4,25,57)	893.0 (± 30.66)	894.4 (± 39.22)		
C5D1 (pre-dose) (n=1,3,0,4,20,45)	85.99 (± 192.0)	116.4 (± 54.0)		
C5D1 (EOI) (n=1,3,0,4,20,45)	852.8 (± 24.77)	753.2 (± 41.32)		

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentrations of Durvalumab

End point title	Serum Concentrations of Durvalumab ^[31]
-----------------	--

End point description:

Serum concentrations of durvalumab are reported. The PK evaluable durvalumab population included all participants who received at least one dose of durvalumab and who had at least one reportable PK concentration. Here, n (number analyzed) denotes those participants who were analyzed for the specified time points. The arbitrary numbers 0.99999 and 99999 signified that the geometric mean and geometric CV% were not calculated at the time point. This was because, as per sponsor convention, three observations > Lower Limit of Quantification were required as a minimum for a plasma concentration to be summarised. Otherwise, the statistics were not calculated at the time point for the specified arm. The arbitrary numbers 999.99 and 9999.9 signified that the geometric mean and geometric CV% could not be calculated as no participant was analysed at that time point for the specified arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	3	8
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (EOI) (n=7,7,3,8,70)	292.5 (± 11.72)	374.5 (± 27.50)	309.0 (± 11.58)	380.7 (± 56.89)
C2D1 (pre-dose) (n=5,6,3,7,61)	35.97 (± 51.44)	14.39 (± 5129)	50.52 (± 57.30)	59.97 (± 176.7)
C5D1 (pre-dose) (n=1,3,0,4,45)	0.99999 (± 99999)	74.52 (± 28.32)	999.99 (± 9999.9)	175.9 (± 43.50)
C5D1 (EOI) (n=1,3,0,4,44)	0.99999 (± 99999)	522.1 (± 46.72)	999.99 (± 9999.9)	664.5 (± 28.14)

End point values	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (EOI) (n=7,7,3,8,70)	345.8 (± 324.2)			
C2D1 (pre-dose) (n=5,6,3,7,61)	86.20 (± 97.95)			
C5D1 (pre-dose) (n=1,3,0,4,45)	137.9 (± 48.85)			
C5D1 (EOI) (n=1,3,0,4,44)	597.9 (± 23.40)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)

End point title	Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU) ^[32]
-----------------	---

End point description:

Plasma concentrations of gemcitabine and metabolite dFdU are reported. The PK evaluable gemcitabine population included all participants who received at least one dose of gemcitabine and who had at least one reportable PK concentration. Here, n (number analyzed) denotes those participants who were analyzed for the specified time points. The arbitrary numbers 0.99999 and 99999 signified that the geometric mean and geometric CV% were not calculated at the time point. This was because, as per sponsor convention, three observations > Lower Limit of Quantification were required as a minimum for a plasma concentration to be summarised. Otherwise, the statistics were not calculated at the time point for the specified arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	57	38
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Gemcitabine C1D1 (EOI) (n=7,7,54,36,65)	3194 (± 64.74)	4659 (± 67.41)	3301 (± 192.0)	3315 (± 135.4)
Gemcitabine C4D1 (pre-dose) (n=2,4,33,25,50)	0.99999 (± 99999)	0.99999 (± 99999)	0.99999 (± 99999)	0.99999 (± 99999)
Gemcitabine C4D1 (EOI) (n=2,4,28,25,49)	0.99999 (± 99999)	3530 (± 48.11)	1748 (± 236.5)	1431 (± 446.3)
dFdU C1D1 (EOI) (n=7,7,54,36,65)	33700 (± 14.70)	32160 (± 17.67)	29510 (± 113.4)	32350 (± 17.10)
dFdU C4D1 (pre-dose) (n=2,4,33,25,50)	0.99999 (± 99999)	434.6 (± 344.7)	245.1 (± 361.5)	149.9 (± 147.0)
dFdU C4D1 (EOI) (n=2,4,28,25,49)	0.99999 (± 99999)	34550 (± 35.37)	23900 (± 189.1)	21970 (± 130.3)

End point values	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Gemcitabine C1D1 (EOI) (n=7,7,54,36,65)	4086 (± 148.9)			
Gemcitabine C4D1 (pre-dose) (n=2,4,33,25,50)	0.99999 (± 99999)			
Gemcitabine C4D1 (EOI) (n=2,4,28,25,49)	2998 (± 151.3)			
dFdU C1D1 (EOI) (n=7,7,54,36,65)	26300 (± 163.9)			
dFdU C4D1 (pre-dose) (n=2,4,33,25,50)	177.5 (± 170.0)			
dFdU C4D1 (EOI) (n=2,4,28,25,49)	27260 (± 43.07)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations of Nab-paclitaxel

End point title	Plasma Concentrations of Nab-paclitaxel ^[33]
-----------------	---

End point description:

Plasma concentrations of nab-paclitaxel are reported. The PK evaluable nab-paclitaxel population included all participants who received at least one dose of nab-paclitaxel and who had at least one reportable PK concentration. Here, n (number analyzed) denotes those participants who were analyzed for the specified time points. The arbitrary numbers 0.99999 and 99999 signified that the geometric mean and geometric CV% were not calculated at the time point. This was because, as per sponsor convention, three observations > Lower Limit of Quantification were required as a minimum for a plasma concentration to be summarised. Otherwise, the statistics were not calculated at the time point for the specified arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Ten mins (\pm 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-expansion, Gem + nab-pacli	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	60	38
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (EOI) (n=7,7,58,35,69)	1711 (\pm 80.37)	2685 (\pm 63.55)	2381 (\pm 105.2)	2711 (\pm 81.67)
C4D1 (pre-dose) (n=2,4,35,24,47)	0.99999 (\pm 99999)	0.99999 (\pm 99999)	0.99999 (\pm 99999)	0.99999 (\pm 99999)
C4D1 (EOI) (n=2,4,31,24,48)	0.99999 (\pm 99999)	1474 (\pm 96.12)	1825 (\pm 178.1)	1445 (\pm 145.8)

End point values	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (EOI) (n=7,7,58,35,69)	2611 (\pm 142.0)			
C4D1 (pre-dose) (n=2,4,35,24,47)	0.99999 (\pm 99999)			
C4D1 (EOI) (n=2,4,31,24,48)	1747 (\pm 99.26)			

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 through 172.1 weeks (maximum observed duration)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

Reporting groups

Reporting group title	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli
-----------------------	--

Reporting group description: -

Reporting group title	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli
-----------------------	--

Reporting group description: -

Reporting group title	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
-----------------------	--

Reporting group description: -

Reporting group title	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX
-----------------------	--

Reporting group description: -

Reporting group title	Dose-expansion, Gem + nab-pacli
-----------------------	---------------------------------

Reporting group description: -

Reporting group title	Dose-expansion, Ole 3000 mg + Gem + nab-pacli
-----------------------	---

Reporting group description: -

Reporting group title	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli
-----------------------	---

Reporting group description: -

Serious adverse events	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacli	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 7 (57.14%)	6 / 7 (85.71%)	0 / 3 (0.00%)
number of deaths (all causes)	7	7	3
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant ascites			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Shock			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Generalised oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pulmonary embolism			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lumbar vertebral fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraventricular haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular			

coagulation				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Febrile neutropenia				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Neutropenia				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Haemolytic uraemic syndrome				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Splenic infarction				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Thrombotic microangiopathy				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Eye disorders				
Vision blurred				
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Gastrointestinal disorders				
Abdominal pain				
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

Constipation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder rupture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bullous impetigo			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 8 (50.00%)	34 / 62 (54.84%)	24 / 38 (63.16%)
number of deaths (all causes)	8	47	32
number of deaths resulting from adverse events	0	3	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant ascites			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Shock			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Localised oedema			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)	5 / 62 (8.06%)	3 / 38 (7.89%)
occurrences causally related to treatment / all	0 / 0	3 / 6	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lumbar vertebral fracture			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraventricular haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Febrile neutropenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolytic uraemic syndrome			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Colitis			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 8 (25.00%)	4 / 62 (6.45%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	1 / 2	2 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	1 / 8 (12.50%)	5 / 62 (8.06%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 1	3 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary obstruction			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder rupture			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bullous impetigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	2 / 38 (5.26%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	1 / 2	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 8 (0.00%)	4 / 62 (6.45%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	1 / 8 (12.50%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacl		
Total subjects affected by serious adverse events			
subjects affected / exposed	37 / 70 (52.86%)		
number of deaths (all causes)	53		
number of deaths resulting from adverse events	3		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant ascites			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Shock			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Embolism			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Localised oedema			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised oedema			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	8 / 70 (11.43%)		
occurrences causally related to treatment / all	7 / 9		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Product issues			

Device occlusion			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Lumbar vertebral fracture			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocarditis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral ischaemia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Haemorrhage intracranial			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Intraventricular haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemolytic uraemic syndrome			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Splenic infarction			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombotic microangiopathy			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Vision blurred			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Ascites			

subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Duodenal obstruction				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	2 / 70 (2.86%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus paralytic				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestinal haemorrhage				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Impaired gastric emptying				

subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Obstruction gastric			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic colitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Biliary obstruction			

subjects affected / exposed	3 / 70 (4.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cholestasis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder rupture			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Jaundice cholestatic			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Rash maculo-papular			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences causally related to treatment / all	3 / 5		
deaths causally related to treatment / all	0 / 0		
Glomerulonephritis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bacterial infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biliary sepsis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Abdominal infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Biliary tract infection				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bullous impetigo				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterocolitis infectious				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic infection				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia bacteraemia				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Liver abscess				

subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal candidiasis				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumocystis jirovecii pneumonia				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	3 / 70 (4.29%)			
occurrences causally related to treatment / all	2 / 4			
deaths causally related to treatment / all	0 / 1			
Urinary tract infection				
subjects affected / exposed	1 / 70 (1.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Tooth abscess				
subjects affected / exposed	0 / 70 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spontaneous bacterial peritonitis				

subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COVID-19			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Electrolyte imbalance			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Dose-escalation, Ole 1500 mg + Durva + Gem + nab-pacl	Dose-escalation, Ole 3000 mg + Durva + Gem + nab-pacl	Dose-escalation, Ole 1500 mg + Durva + mFOLFOX
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	7 / 7 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cancer fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Capillary leak syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cryoglobulinaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Embolism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	2 / 7 (28.57%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Phlebitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Subclavian vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Superficial vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombosis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Venous thrombosis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Asthenia			

subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	2	2	0
Catheter site pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	6 / 7 (85.71%)	7 / 7 (100.00%)	2 / 3 (66.67%)
occurrences (all)	6	9	2
Feeling abnormal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypothermia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Infusion site extravasation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Illness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	2 / 7 (28.57%)	3 / 7 (42.86%)	0 / 3 (0.00%)
occurrences (all)	4	4	0
Pain			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Peripheral swelling			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	3 / 7 (42.86%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	4	2	0
Temperature intolerance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Unevaluable event subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Immune system disorders Anaphylactic reaction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Immunisation reaction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Infusion related hypersensitivity reaction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders Breast oedema subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Pelvic discomfort subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

Acute pulmonary oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 7 (14.29%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Dysphonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Bronchiectasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Hiccups			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pulmonary congestion			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Orthopnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nasal ulcer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Throat irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			

subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	2 / 7 (28.57%) 2	0 / 3 (0.00%) 0
Psychiatric disorders			
Depressive symptom			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Depression			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Disorientation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Mania			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mental status changes			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Restlessness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Persistent depressive disorder subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	3 / 7 (42.86%) 6	0 / 3 (0.00%) 0
Alanine aminotransferase decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Amylase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 3 (33.33%) 1
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	4 / 7 (57.14%) 4	0 / 3 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 7 (14.29%) 3	0 / 3 (0.00%) 0
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Liver function test increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Haemoglobin decreased			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood oestrogen decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood glucose decreased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Blood glucose increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
White blood cell count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Neutrophil count			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	1 / 3 (33.33%)
occurrences (all)	0	3	2
Platelet count decreased			
subjects affected / exposed	1 / 7 (14.29%)	3 / 7 (42.86%)	1 / 3 (33.33%)
occurrences (all)	2	6	2
Urine output decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin I increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Foot fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural complication			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Subcutaneous haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Pericardial effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Angina pectoris subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Nervous system disorders			
Amnesia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Akathisia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Ageusia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Burning sensation subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Cerebral ischaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Lethargy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Hypoaesthesia			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypersomnia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Dysgeusia			
subjects affected / exposed	0 / 7 (0.00%)	3 / 7 (42.86%)	2 / 3 (66.67%)
occurrences (all)	0	3	2
Memory impairment			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	3 / 7 (42.86%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	5	1	0
Polyneuropathy in malignant disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neurotoxicity			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Presyncope			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Restless legs syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	2 / 3 (66.67%)
occurrences (all)	2	13	3
Lymphopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Splenic infarction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Febrile neutropenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	3 / 7 (42.86%)	3 / 7 (42.86%)	1 / 3 (33.33%)
occurrences (all)	4	4	2
Haemolytic uraemic syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	2 / 3 (66.67%)
occurrences (all)	5	3	3
Splenic vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Hypoacusis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Meniere's disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vertigo			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypermetropia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Glaucoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye allergy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Orbital haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Periorbital pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Photopsia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Visual field defect			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lacrimation increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	2 / 3 (66.67%)
occurrences (all)	2	3	2
Abdominal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal tenderness			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Anal incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 7 (28.57%)	5 / 7 (71.43%)	2 / 3 (66.67%)
occurrences (all)	2	5	2
Diarrhoea			
subjects affected / exposed	5 / 7 (71.43%)	2 / 7 (28.57%)	1 / 3 (33.33%)
occurrences (all)	6	2	1
Dry mouth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Mouth ulceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed	6 / 7 (85.71%)	6 / 7 (85.71%)	2 / 3 (66.67%)
occurrences (all)	6	8	2
Odynophagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema mouth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periodontal disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Proctitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tongue blistering			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 4	2 / 7 (28.57%) 2	1 / 3 (33.33%) 1
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cholangitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Congestive hepatopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertransaminasaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Portal vein occlusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Portal vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhagic hepatic cyst			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	1 / 7 (14.29%)	3 / 7 (42.86%)	0 / 3 (0.00%)
occurrences (all)	1	3	0
Erythema			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hair colour changes			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nail discolouration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Onychalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onychomadesis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Purpura			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Rash erythematous			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0

Skin discolouration subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Vitiligo subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Renal and urinary disorders			
Acute kidney injury subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Micturition urgency subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Nephrolithiasis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dysuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urinary tract pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	1 / 3 (33.33%)
occurrences (all)	2	2	2
Muscle spasms			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Flank pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Limb discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Muscle tightness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Synovial cyst			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myopathy			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myositis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Rheumatoid arthritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Diverticulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
External ear cellulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Herpes simplex			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Liver abscess			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Sinusitis			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mucosal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oesophageal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sputum purulent			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Tooth infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Vaginal infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	4 / 7 (57.14%) 4	3 / 7 (42.86%) 3	1 / 3 (33.33%) 1
Dehydration subjects affected / exposed occurrences (all)	4 / 7 (57.14%) 4	2 / 7 (28.57%) 2	1 / 3 (33.33%) 1
Gout subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	3 / 7 (42.86%) 5	0 / 3 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	2 / 7 (28.57%) 2	0 / 3 (0.00%) 0
Hypocalcaemia			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Hypoglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 7 (14.29%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	1	4	0
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Hypophosphataemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypovolaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Dose-escalation, Ole 3000 mg + Durva + mFOLFOX	Dose-expansion, Gem + nab-pacl	Dose-expansion, Ole 3000 mg + Gem + nab-pacl
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)	60 / 62 (96.77%)	36 / 38 (94.74%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Cancer fatigue			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Cancer pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Capillary leak syndrome			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Cryoglobulinaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	5 / 62 (8.06%)	2 / 38 (5.26%)
occurrences (all)	0	5	3
Embolism			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	3 / 38 (7.89%)
occurrences (all)	0	0	4
Orthostatic hypotension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Hot flush			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 8 (12.50%)	2 / 62 (3.23%)	3 / 38 (7.89%)
occurrences (all)	1	2	7
Hypotension			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	4 / 38 (10.53%)
occurrences (all)	1	3	4

Haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Phlebitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Subclavian vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Superficial vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Venous thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	8 / 62 (12.90%)	4 / 38 (10.53%)
occurrences (all)	0	9	9
Catheter site pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	6 / 38 (15.79%)
occurrences (all)	0	3	11
Early satiety			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Fatigue			

subjects affected / exposed	6 / 8 (75.00%)	30 / 62 (48.39%)	25 / 38 (65.79%)
occurrences (all)	7	33	60
Feeling abnormal			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Gait disturbance			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Generalised oedema			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Hypothermia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Influenza like illness			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Infusion site extravasation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Injection site haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Injection site pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Injection site reaction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Illness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			

subjects affected / exposed	2 / 8 (25.00%)	13 / 62 (20.97%)	12 / 38 (31.58%)
occurrences (all)	2	15	21
Pain			
subjects affected / exposed	1 / 8 (12.50%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	1	1	2
Peripheral swelling			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Pyrexia			
subjects affected / exposed	1 / 8 (12.50%)	10 / 62 (16.13%)	10 / 38 (26.32%)
occurrences (all)	1	14	16
Temperature intolerance			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	3 / 38 (7.89%)
occurrences (all)	1	3	3
Malaise			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	1 / 38 (2.63%)
occurrences (all)	2	3	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Unevaluable event			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Immunisation reaction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0

Infusion related hypersensitivity reaction subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Reproductive system and breast disorders			
Breast oedema subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	2 / 62 (3.23%) 2	0 / 38 (0.00%) 0
Pelvic discomfort subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	0 / 38 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	1 / 38 (2.63%) 1
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	0 / 38 (0.00%) 0
Cough			

subjects affected / exposed	0 / 8 (0.00%)	5 / 62 (8.06%)	4 / 38 (10.53%)
occurrences (all)	0	6	5
Dysphonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 8 (0.00%)	6 / 62 (9.68%)	6 / 38 (15.79%)
occurrences (all)	0	7	6
Bronchiectasis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	2 / 38 (5.26%)
occurrences (all)	0	3	2
Hiccups			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	1 / 38 (2.63%)
occurrences (all)	1	3	2
Hypoxia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Pulmonary congestion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Orthopnoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Pneumonitis			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Nasal ulcer			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 8 (0.00%)	4 / 62 (6.45%)	2 / 38 (5.26%)
occurrences (all)	0	4	2
Pulmonary oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)	5 / 62 (8.06%)	0 / 38 (0.00%)
occurrences (all)	0	5	0
Throat irritation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Sinus congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depressive symptom			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Agitation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Anxiety			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	4 / 38 (10.53%)
occurrences (all)	1	3	4

Confusional state			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Disorientation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	5 / 38 (13.16%)
occurrences (all)	1	3	9
Mania			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Mental status changes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Tic			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Persistent depressive disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 8 (37.50%)	11 / 62 (17.74%)	8 / 38 (21.05%)
occurrences (all)	3	14	9
Alanine aminotransferase decreased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Amylase increased			

subjects affected / exposed	1 / 8 (12.50%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	1	1	0
Alanine aminotransferase increased			
subjects affected / exposed	2 / 8 (25.00%)	8 / 62 (12.90%)	9 / 38 (23.68%)
occurrences (all)	2	9	10
Blood bilirubin increased			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	3 / 38 (7.89%)
occurrences (all)	1	3	3
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	2 / 38 (5.26%)
occurrences (all)	1	3	2
Blood albumin decreased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
International normalised ratio increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	1	0	1
Liver function test increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Haemoglobin decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 8 (12.50%)	6 / 62 (9.68%)	1 / 38 (2.63%)
occurrences (all)	2	8	1
Blood oestrogen decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Blood magnesium decreased			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Blood glucose decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences (all)	0	2	0
Blood glucose increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Weight increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 8 (12.50%)	4 / 62 (6.45%)	7 / 38 (18.42%)
occurrences (all)	1	4	7
White blood cell count increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
White blood cell count decreased			
subjects affected / exposed	2 / 8 (25.00%)	6 / 62 (9.68%)	6 / 38 (15.79%)
occurrences (all)	2	19	8
Lymphocyte count decreased			
subjects affected / exposed	2 / 8 (25.00%)	4 / 62 (6.45%)	2 / 38 (5.26%)
occurrences (all)	3	11	2
Neutrophil count			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	3 / 8 (37.50%)	19 / 62 (30.65%)	8 / 38 (21.05%)
occurrences (all)	4	41	13

Platelet count decreased subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3	13 / 62 (20.97%) 39	9 / 38 (23.68%) 24
Urine output decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Troponin I increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	0 / 38 (0.00%) 0
Injury, poisoning and procedural complications			
Animal bite subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	3 / 62 (4.84%) 5	2 / 38 (5.26%) 2
Foot fracture subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Infusion related reaction subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Limb injury subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Procedural complication subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Rib fracture subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Skin abrasion			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Thermal burn			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Subcutaneous haematoma			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Pericardial effusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Angina pectoris			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Tachycardia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	3 / 38 (7.89%)
occurrences (all)	0	2	3
Supraventricular tachycardia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Nervous system disorders			
Amnesia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Akathisia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Ageusia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 8 (12.50%)	6 / 62 (9.68%)	7 / 38 (18.42%)
occurrences (all)	1	7	7
Disturbance in attention			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Cerebral ischaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hypersomnia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	1 / 8 (12.50%)	6 / 62 (9.68%)	3 / 38 (7.89%)
occurrences (all)	1	6	3
Dysgeusia			
subjects affected / exposed	0 / 8 (0.00%)	10 / 62 (16.13%)	5 / 38 (13.16%)
occurrences (all)	0	10	10
Memory impairment			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	2 / 8 (25.00%)	11 / 62 (17.74%)	11 / 38 (28.95%)
occurrences (all)	2	13	12
Polyneuropathy in malignant disease			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 8 (12.50%)	9 / 62 (14.52%)	11 / 38 (28.95%)
occurrences (all)	1	11	17
Peripheral motor neuropathy			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Paraesthesia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Neurotoxicity			
subjects affected / exposed	0 / 8 (0.00%)	4 / 62 (6.45%)	1 / 38 (2.63%)
occurrences (all)	0	4	1
Presyncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	1 / 8 (12.50%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	1	1	0
Restless legs syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Syncope			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Taste disorder			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 8 (12.50%)	22 / 62 (35.48%)	14 / 38 (36.84%)
occurrences (all)	1	37	25
Lymphopenia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences (all)	0	2	0
Lymphadenopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	3
Leukocytosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Splenic infarction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Febrile neutropenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)	17 / 62 (27.42%)	14 / 38 (36.84%)
occurrences (all)	0	25	15
Haemolytic uraemic syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0

Thrombocytosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	2 / 62 (3.23%) 2	0 / 38 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	6 / 62 (9.68%) 8	7 / 38 (18.42%) 10
Splenic vein thrombosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Ear and labyrinth disorders			
Ear congestion subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Hypoacusis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Meniere's disease subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	0 / 38 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Hypermetropia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Eyelid irritation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Eyelid ptosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Glaucoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Eye allergy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Orbital haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Periorbital oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Periorbital pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Photopsia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Visual field defect			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Visual impairment			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Vitreous floaters			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 8 (12.50%)	12 / 62 (19.35%)	6 / 38 (15.79%)
occurrences (all)	1	13	7
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Abdominal distension			
subjects affected / exposed	2 / 8 (25.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	2	2	2
Abdominal pain upper			
subjects affected / exposed	1 / 8 (12.50%)	5 / 62 (8.06%)	4 / 38 (10.53%)
occurrences (all)	1	5	4
Abdominal tenderness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Anorectal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	1 / 8 (12.50%)	2 / 62 (3.23%)	3 / 38 (7.89%)
occurrences (all)	1	2	3

Dysphagia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	2 / 8 (25.00%)	10 / 62 (16.13%)	15 / 38 (39.47%)
occurrences (all)	2	13	21
Diarrhoea			
subjects affected / exposed	5 / 8 (62.50%)	18 / 62 (29.03%)	14 / 38 (36.84%)
occurrences (all)	6	26	29
Dry mouth			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	2 / 38 (5.26%)
occurrences (all)	0	3	2
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	4 / 38 (10.53%)
occurrences (all)	0	2	4
Colitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Faeces discoloured			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	2 / 8 (25.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	2	1	0
Gastritis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0

Gingival bleeding			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Gingival pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Mouth ulceration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	4 / 8 (50.00%)	26 / 62 (41.94%)	26 / 38 (68.42%)
occurrences (all)	5	34	70
Odynophagia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Oedema mouth			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Melaena			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Oral pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0

Pancreatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Periodontal disease			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Proctitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	3 / 8 (37.50%)	5 / 62 (8.06%)	3 / 38 (7.89%)
occurrences (all)	3	5	5
Tongue blistering			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	3 / 8 (37.50%)	15 / 62 (24.19%)	12 / 38 (31.58%)
occurrences (all)	3	21	18
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Cholangitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Congestive hepatopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hepatitis			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hypertransaminasaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Portal vein occlusion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Portal vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Haemorrhagic hepatic cyst			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Dermal cyst			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	4 / 38 (10.53%)
occurrences (all)	0	0	4
Dry skin			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	5 / 38 (13.16%)
occurrences (all)	0	2	5
Alopecia			
subjects affected / exposed	0 / 8 (0.00%)	12 / 62 (19.35%)	11 / 38 (28.95%)
occurrences (all)	0	12	11

Erythema			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Hair colour changes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	5
Nail discolouration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Night sweats			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Onychalgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Onycholysis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Onychomadesis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	2	0	1
Petechiae			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Pruritus			

subjects affected / exposed	1 / 8 (12.50%)	5 / 62 (8.06%)	6 / 38 (15.79%)
occurrences (all)	1	5	10
Purpura			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	1 / 8 (12.50%)	4 / 62 (6.45%)	6 / 38 (15.79%)
occurrences (all)	1	4	15
Rash erythematous			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Skin fissures			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Rash pruritic			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Skin discolouration			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Skin exfoliation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	0 / 8 (0.00%)	5 / 62 (8.06%)	6 / 38 (15.79%)
occurrences (all)	0	5	17
Skin hyperpigmentation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Skin ulcer			

subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	2
Urticaria			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Vitiligo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2
Renal failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences (all)	0	2	0
Micturition urgency			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Proteinuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Dysuria			
subjects affected / exposed	1 / 8 (12.50%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences (all)	1	3	0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0

Urinary incontinence subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Urinary retention subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 2
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	1 / 38 (2.63%) 1
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	8 / 62 (12.90%) 10	7 / 38 (18.42%) 9
Muscle spasms subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2	0 / 62 (0.00%) 0	4 / 38 (10.53%) 7
Bone pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	4 / 62 (6.45%) 4	1 / 38 (2.63%) 1
Flank pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	2 / 38 (5.26%) 2
Joint swelling subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 62 (0.00%) 0	0 / 38 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 62 (1.61%) 1	0 / 38 (0.00%) 0
Back pain			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	3 / 38 (7.89%)
occurrences (all)	0	1	3
Muscle tightness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 8 (0.00%)	8 / 62 (12.90%)	4 / 38 (10.53%)
occurrences (all)	0	8	4
Musculoskeletal chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Synovial cyst			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Myopathy			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Myositis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)	3 / 62 (4.84%)	4 / 38 (10.53%)
occurrences (all)	0	3	6
Rheumatoid arthritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Myalgia			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	3 / 62 (4.84%) 3	8 / 38 (21.05%) 10
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	2 / 38 (5.26%)
occurrences (all)	0	0	3
Abdominal infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Bacteraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Candida infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	1	0	1
Catheter site infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Conjunctivitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
External ear cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Lower respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	2 / 38 (5.26%)
occurrences (all)	0	1	2

Gastroenteritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Herpes simplex			
subjects affected / exposed	1 / 8 (12.50%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Liver abscess			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Fungal infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Rash pustular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Sepsis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Mucosal infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	0 / 38 (0.00%)
occurrences (all)	0	2	0
Oesophageal infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0

Oral candidiasis			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Otitis media			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Paronychia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Sputum purulent			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Tonsillitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	2 / 62 (3.23%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Urinary tract infection			
subjects affected / exposed	1 / 8 (12.50%)	2 / 62 (3.23%)	2 / 38 (5.26%)
occurrences (all)	1	2	3
Vaginal infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	3 / 8 (37.50%)	16 / 62 (25.81%)	15 / 38 (39.47%)
occurrences (all)	3	17	58
Dehydration			
subjects affected / exposed	2 / 8 (25.00%)	6 / 62 (9.68%)	1 / 38 (2.63%)
occurrences (all)	2	6	1
Gout			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	2 / 8 (25.00%)	4 / 62 (6.45%)	2 / 38 (5.26%)
occurrences (all)	3	9	3
Hyperkalaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	1 / 38 (2.63%)
occurrences (all)	0	1	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 8 (12.50%)	3 / 62 (4.84%)	2 / 38 (5.26%)
occurrences (all)	1	3	2
Hypocalcaemia			
subjects affected / exposed	1 / 8 (12.50%)	2 / 62 (3.23%)	2 / 38 (5.26%)
occurrences (all)	1	3	2
Hypoglycaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 8 (0.00%)	4 / 62 (6.45%)	2 / 38 (5.26%)
occurrences (all)	0	5	2
Hypomagnesaemia			
subjects affected / exposed	1 / 8 (12.50%)	4 / 62 (6.45%)	3 / 38 (7.89%)
occurrences (all)	1	8	3
Hyponatraemia			
subjects affected / exposed	2 / 8 (25.00%)	8 / 62 (12.90%)	0 / 38 (0.00%)
occurrences (all)	3	9	0
Hypophosphataemia			

subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	2	0
Hypovolaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 62 (1.61%)	0 / 38 (0.00%)
occurrences (all)	0	1	0
Iron deficiency			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 62 (0.00%)	1 / 38 (2.63%)
occurrences (all)	0	0	1

Non-serious adverse events	Dose-expansion, Ole 3000 mg + Durva + Gem + nab-pacli		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	70 / 70 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Cancer fatigue			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Cancer pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Capillary leak syndrome			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Cryoglobulinaemia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Deep vein thrombosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Embolism			

subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Flushing			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	3		
Orthostatic hypotension			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	15		
Hypotension			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Haematoma			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Phlebitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Subclavian vein thrombosis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Superficial vein thrombosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Thrombosis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Venous thrombosis			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Asthenia			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	10		
Catheter site pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	9 / 70 (12.86%)		
occurrences (all)	10		
Early satiety			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	41 / 70 (58.57%)		
occurrences (all)	54		
Feeling abnormal			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gait disturbance			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Generalised oedema			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypothermia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Localised oedema			

subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Influenza like illness			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	10		
Infusion site extravasation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Injection site haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Injection site pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Illness			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	28 / 70 (40.00%)		
occurrences (all)	41		
Pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Peripheral swelling			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	18 / 70 (25.71%)		
occurrences (all)	26		
Temperature intolerance			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Oedema			

subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Malaise			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Mucosal inflammation			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Non-cardiac chest pain			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	3		
Unevaluable event			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Immunisation reaction			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Infusion related hypersensitivity reaction			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Breast oedema			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Erectile dysfunction			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pelvic discomfort			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Prostatitis			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Vaginal discharge			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Vaginal haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Dyspnoea exertional			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	11 / 70 (15.71%)		
occurrences (all)	13		
Dysphonia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
Dyspnoea			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	7		
Bronchiectasis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	5 / 70 (7.14%)		
occurrences (all)	6		
Hiccups			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypoxia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Nasal congestion			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Pulmonary congestion			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Orthopnoea			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Pneumonitis			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	4		
Nasal ulcer			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Pulmonary oedema			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Rhinitis allergic			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Rhinorrhoea			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Throat irritation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Upper-airway cough syndrome			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Sinus congestion			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depressive symptom			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Agitation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Confusional state			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Depression			
subjects affected / exposed	5 / 70 (7.14%)		
occurrences (all)	5		
Disorientation			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	7		
Mania			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		

Mental status changes subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Restlessness subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Tic subjects affected / exposed occurrences (all)	1 / 70 (1.43%) 1		
Persistent depressive disorder subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	15 / 70 (21.43%) 22		
Alanine aminotransferase decreased subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Amylase increased subjects affected / exposed occurrences (all)	1 / 70 (1.43%) 1		
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	16 / 70 (22.86%) 22		
Blood bilirubin increased subjects affected / exposed occurrences (all)	2 / 70 (2.86%) 2		
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	8 / 70 (11.43%) 9		
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
International normalised ratio increased			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Lipase increased			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Liver function test increased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Haemoglobin decreased			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Gamma-glutamyltransferase increased			
subjects affected / exposed	8 / 70 (11.43%)		
occurrences (all)	10		
Blood oestrogen decreased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Blood magnesium decreased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Blood glucose decreased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	8 / 70 (11.43%)		
occurrences (all)	10		
Blood glucose increased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Weight increased			

subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	4		
Weight decreased			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	8		
White blood cell count increased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	19		
Lymphocyte count decreased			
subjects affected / exposed	6 / 70 (8.57%)		
occurrences (all)	8		
Neutrophil count			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	24 / 70 (34.29%)		
occurrences (all)	49		
Platelet count decreased			
subjects affected / exposed	20 / 70 (28.57%)		
occurrences (all)	50		
Urine output decreased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Troponin I increased			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Contusion			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
Fall			
subjects affected / exposed	5 / 70 (7.14%)		
occurrences (all)	7		
Foot fracture			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Infusion related reaction			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Limb injury			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Procedural complication			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Rib fracture			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Skin abrasion			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Skin laceration			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Spinal compression fracture			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Thermal burn			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Wound			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Subcutaneous haematoma			

subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Cardiac disorders			
Pericardial effusion subjects affected / exposed occurrences (all)	1 / 70 (1.43%) 1		
Atrioventricular block subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Angina pectoris subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Tachycardia subjects affected / exposed occurrences (all)	3 / 70 (4.29%) 4		
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Nervous system disorders			
Amnesia subjects affected / exposed occurrences (all)	1 / 70 (1.43%) 1		
Akathisia subjects affected / exposed occurrences (all)	2 / 70 (2.86%) 2		
Ageusia subjects affected / exposed occurrences (all)	1 / 70 (1.43%) 1		
Burning sensation subjects affected / exposed occurrences (all)	0 / 70 (0.00%) 0		
Dizziness subjects affected / exposed occurrences (all)	6 / 70 (8.57%) 9		
Disturbance in attention			

subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Cerebral ischaemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hypoaesthesia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hypersomnia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	12 / 70 (17.14%)		
occurrences (all)	13		
Dysgeusia			
subjects affected / exposed	12 / 70 (17.14%)		
occurrences (all)	13		
Memory impairment			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Neuralgia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	13 / 70 (18.57%)		
occurrences (all)	17		
Polyneuropathy in malignant disease			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Peripheral sensory neuropathy			
subjects affected / exposed	15 / 70 (21.43%)		
occurrences (all)	17		
Peripheral motor neuropathy			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Neurotoxicity			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Presyncope			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Sciatica			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Restless legs syndrome			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Syncope			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Taste disorder			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	16 / 70 (22.86%)		
occurrences (all)	36		
Lymphopenia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Lymphadenopathy			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		

Leukopenia			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	8		
Leukocytosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Splenic infarction			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Febrile neutropenia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Anaemia			
subjects affected / exposed	27 / 70 (38.57%)		
occurrences (all)	41		
Haemolytic uraemic syndrome			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Thrombotic microangiopathy			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Thrombocytosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Thrombocytopenia			
subjects affected / exposed	13 / 70 (18.57%)		
occurrences (all)	24		
Splenic vein thrombosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Ear pain			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
Hypoacusis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Meniere's disease			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Vertigo			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Dry eye			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypermetropia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Eye irritation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Eyelid irritation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Eyelid ptosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Glaucoma			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		

Eye allergy			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Orbital haematoma			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Periorbital oedema			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Periorbital pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Photopsia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	4		
Visual field defect			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Vitreous floaters			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Lacrimation increased			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Ocular hyperaemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	13 / 70 (18.57%)		
occurrences (all)	16		
Abdominal discomfort			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Abdominal distension			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Abdominal pain upper			
subjects affected / exposed	5 / 70 (7.14%)		
occurrences (all)	5		
Abdominal tenderness			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Anal incontinence			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Anorectal discomfort			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Ascites			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Dysphagia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	18 / 70 (25.71%)		
occurrences (all)	28		
Diarrhoea			
subjects affected / exposed	36 / 70 (51.43%)		
occurrences (all)	63		
Dry mouth			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	4		
Dyspepsia			

subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	7		
Colitis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Faeces discoloured			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Flatulence			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Gastritis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gastrointestinal pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Inguinal hernia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gingival pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Haematochezia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Haemorrhoids			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Mouth ulceration			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Nausea			
subjects affected / exposed	41 / 70 (58.57%)		
occurrences (all)	49		
Odynophagia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Oedema mouth			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Melaena			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Oral pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pancreatitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Periodontal disease			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Proctitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Oral dysaesthesia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Stomatitis			

subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	7		
Tongue blistering			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	16 / 70 (22.86%)		
occurrences (all)	23		
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Cholangitis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Congestive hepatopathy			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hepatitis			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	6		
Hypertransaminaemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Portal vein occlusion			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Portal vein thrombosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Haemorrhagic hepatic cyst			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		

Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Dermal cyst			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Dermatitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	5		
Dry skin			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Alopecia			
subjects affected / exposed	25 / 70 (35.71%)		
occurrences (all)	26		
Erythema			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hair colour changes			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Nail discolouration			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Night sweats			

subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Onychalgia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Onycholysis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Onychomadesis			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Pain of skin			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Petechiae			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	16 / 70 (22.86%)		
occurrences (all)	18		
Purpura			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	13 / 70 (18.57%)		
occurrences (all)	14		
Rash erythematous			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Rash macular			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		

Skin fissures			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Rash papular			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Skin discolouration			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
Skin exfoliation			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	12 / 70 (17.14%)		
occurrences (all)	19		
Skin hyperpigmentation			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Skin ulcer			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Vitiligo			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	4		
Renal failure			

subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Micturition urgency			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Nephrolithiasis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Dysuria			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Urinary incontinence			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Urinary retention			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Urinary tract pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		

Hypothyroidism			
subjects affected / exposed	7 / 70 (10.00%)		
occurrences (all)	7		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	14		
Muscle spasms			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Bone pain			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Flank pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Limb discomfort			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	10		
Muscle tightness			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	8 / 70 (11.43%)		
occurrences (all)	8		
Musculoskeletal chest pain			
subjects affected / exposed	4 / 70 (5.71%)		
occurrences (all)	5		
Musculoskeletal discomfort			

subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Musculoskeletal pain			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Synovial cyst			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Myopathy			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Myositis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	3		
Pain in extremity			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	10		
Rheumatoid arthritis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	14 / 70 (20.00%)		
occurrences (all)	19		
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Abdominal infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Bacteraemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		

Candida infection			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Catheter site infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Diverticulitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
External ear cellulitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Eye infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Lower respiratory tract infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Herpes simplex			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Liver abscess			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		

Fungal infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
Sepsis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Mucosal infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	3		
Oesophageal infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Oral candidiasis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Otitis media			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		

Nasopharyngitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Sputum purulent			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Tonsillitis			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Tooth infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Urinary tract infection			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	6		
Vaginal infection			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	2		
COVID-19			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	21 / 70 (30.00%)		
occurrences (all)	22		
Dehydration			
subjects affected / exposed	10 / 70 (14.29%)		
occurrences (all)	12		
Gout			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypokalaemia			

subjects affected / exposed	8 / 70 (11.43%)		
occurrences (all)	12		
Hyperkalaemia			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Hypoalbuminaemia			
subjects affected / exposed	6 / 70 (8.57%)		
occurrences (all)	7		
Hypocalcaemia			
subjects affected / exposed	3 / 70 (4.29%)		
occurrences (all)	4		
Hypoglycaemia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	3		
Hyperglycaemia			
subjects affected / exposed	6 / 70 (8.57%)		
occurrences (all)	9		
Hypomagnesaemia			
subjects affected / exposed	6 / 70 (8.57%)		
occurrences (all)	9		
Hyponatraemia			
subjects affected / exposed	2 / 70 (2.86%)		
occurrences (all)	2		
Hypophosphataemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Hypovolaemia			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		
Iron deficiency			
subjects affected / exposed	1 / 70 (1.43%)		
occurrences (all)	1		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 70 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 June 2019	<p>Section 3.1.1 (Overview), Figure 2 (3.1.1-2) (Study Flow Diagram [Part 2: Dose Expansion]), Sections 4.1.1 (Number of Subjects), 4.8.2 (Sample Size), and 4.8.7 (Interim Analysis): Revised Part 2 of the study design as detailed next. Cohort A Part 2: Revised number of participants to include an additional 30 participants per treatment arm (now up to 60 participants per treatment arm). Revised significance level to 0.10 (previously 0.15) and increased power to 77% (previously 66%) in Section 4.8.2. Added an interim analysis in Section 4.8.7 when approximately 30 evaluable participants in each treatment arm have been dosed and reach the data cut off criteria. Cohort B Part 2: Revised the sample size to 35 participants per treatment arm. Revised significance level to 0.10 (previously 0.15), revised difference in OR rate to 20% (previously 15%), and increased power to 72% (previously 63%) in Section 4.8.2. Updated total number of participants. Section 3.1.3.4 (Safety Review Committee [SRC]): Added SRC to provide details regarding ongoing safety surveillance of participants during the randomization phase of the study. Section 4.1.2 (Inclusion Criteria): For Criterion 8, Table 5 (4.1.2-1) (Criteria for Adequate Organ and Marrow Function), clarified that $TBL \leq 3 \times ULN$ in presence of documented Gilbert's syndrome or liver metastases is allowed only for participants in Cohort B. Section 4.1.3 (Exclusion Criteria): Revised as- Criterion 5: Clarified that participants with thrombosis due to mechanical obstruction by the tumor that is found incidentally and is asymptomatic and does not require therapy may be enrolled at the investigator's discretion and should be monitored closely. Criterion 21: Added exclusion criterion for participants with known allergy or hypersensitivity to gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, or 5-FU. Section 4.7.2 (Prohibited Concomitant Medications): Added cannabinoids as prohibited concomitant medication for oleclumab treatment arms.</p>
20 December 2019	<p>Section 1.6.1 (Potential Risks): Revised arterial calcifications and arterial ischemic disorder to potential risks for oleclumab. Revised risks for durvalumab. Sections 3.1.1 (Overview), 4.1.1 (Number of Subjects), 4.8.2 (Sample Size), and Figure 2 (3.1.1-2; Study Flow Diagram [Part 2: Dose Expansion]): Revised to reflect a sample size of 70 participants per treatment arm for Cohort A (Part 2 [Dose Expansion]). Section 3.1.4.1 and 10.9 (previously numbered 10.10): Revised toxicity management guidelines in Section 10.9. Section 3.1.4.2: Added new section with information regarding toxicity management guidelines for durvalumab. Section 4.1.7: Added statement in the second paragraph that participants with unconfirmed radiologic PD who were eligible to continue receiving their assigned treatment were to be made aware of the potential benefits and risks of continuing treatment in the setting of PD and must provide a separate written informed consent prior to treatment. Section 4.2.3 (Follow-up Period): Added assessment for pregnancy testing Q4W starting 8 weeks through 28 weeks post last dose during follow up in Table 9 (4.2.3-1; Schedule of Follow-up Procedures [Part 1 (Dose Escalation) and Part 2 (Dose Expansion)]). The frequency of the pregnancy testing was updated to align with contraception requirements in the inclusion criteria and the Summary of Product Characteristics for the chemotherapy drugs. Sections 4.5.1.2 (Oleclumab [MEDI9447] IV Bag Preparation and Administration) and 4.5.1.3 (Durvalumab [MEDI4736] IV Bag Preparation and Administration): Revised to require that participant weight was > 30 kg for fixed dosing of oleclumab and durvalumab due to endotoxin levels. Section 5.3.3 (Adverse Events of Special Interest [AESI] for Durvalumab): Added AESIs of vasculitis, non-infectious meningitis, and non-infectious encephalitis per durvalumab IB edition 15.0.</p>

24 June 2022	Section 4.4.1 (Continued Treatment at Study Completion): New section added to describe the continued treatment period for participants still receiving investigational product at the time of data entry cut off. Sections 1.6.1 (Potential Risks) and 5.3.2.1 (Cardiac Chest Pain, Transient Ischemic Attack, and Thromboembolism): The known and potential risks for oleclumab and durvalumab were updated in line with the most recent information.
--------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Dose escalation phase: Participants not enrolled in oleclumab 750 mg cohort. Dose expansion phase: Outcomes of mFOLFOX cohorts not included as enrollment was not opened. Non-compartmental PK parameters were not calculated due to sparse PK samples.

Notes: